Sam Brusco, Associate Editor07.17.23
Glaukos, an ophthalmic medtech and pharma company focused on glaucoma, corneal disorder, and retinal disease treatment, began a collaboration and marketing deal with Radius XR.
Under the agreement’s terms, Glaukos will become the exclusive sales agent to market, promote, and solicit orders for Radius XR’s wearable patient engagement and diagnostic system in the U.S. Radius will keep leading development and commercialization efforts in the U.S.
Radius XR’s platform is a portable vision diagnostic and patient engagement tool for more efficient eye disease detection and better management and treatment of sight-threatening conditions, according to the company. It combines medical-grade diagnostics, business management tools, and patient education resources in a wearable spatial computing device.
The system lets patients perform self-guided vision tests with minimal supervision as well.
“Today marks a notable milestone for Radius and more importantly, for patients suffering from chronic eye diseases. Glaukos is highly trusted and respected by vision care providers, and this collaboration will provide us with the necessary resources to expedite product development, optimize benefits for eye care providers and enhance the overall quality of care and access for patients," Ammad Khan, Radius CEO told the press. “Through this partnership, Radius will benefit from Glaukos' market-building expertise, leveraging its well-established sales team with extensive clinical knowledge and technical insight to commercialize and drive greater patient access for the Radius XR technology.”
"We are delighted to partner with Radius to strengthen commercialization efforts and expand patient access for Radius’ innovative portable vision diagnostic system," added Thomas Burns, Glaukos chairman and CEO. "We believe the Radius XR platform is a novel technology that can help drive more efficient and improved diagnosis for patients suffering from chronic eye diseases, while also creating efficiency and growth opportunities for eye care practices. This collaboration aligns with our mission to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
Last month, Glaukos began a deal for Celanese to supply its VitalDose drug delivery platform as a component in Glaukos’ iDose TR micro-invasive intraocular implant.
Under the agreement’s terms, Glaukos will become the exclusive sales agent to market, promote, and solicit orders for Radius XR’s wearable patient engagement and diagnostic system in the U.S. Radius will keep leading development and commercialization efforts in the U.S.
Radius XR’s platform is a portable vision diagnostic and patient engagement tool for more efficient eye disease detection and better management and treatment of sight-threatening conditions, according to the company. It combines medical-grade diagnostics, business management tools, and patient education resources in a wearable spatial computing device.
The system lets patients perform self-guided vision tests with minimal supervision as well.
“Today marks a notable milestone for Radius and more importantly, for patients suffering from chronic eye diseases. Glaukos is highly trusted and respected by vision care providers, and this collaboration will provide us with the necessary resources to expedite product development, optimize benefits for eye care providers and enhance the overall quality of care and access for patients," Ammad Khan, Radius CEO told the press. “Through this partnership, Radius will benefit from Glaukos' market-building expertise, leveraging its well-established sales team with extensive clinical knowledge and technical insight to commercialize and drive greater patient access for the Radius XR technology.”
"We are delighted to partner with Radius to strengthen commercialization efforts and expand patient access for Radius’ innovative portable vision diagnostic system," added Thomas Burns, Glaukos chairman and CEO. "We believe the Radius XR platform is a novel technology that can help drive more efficient and improved diagnosis for patients suffering from chronic eye diseases, while also creating efficiency and growth opportunities for eye care practices. This collaboration aligns with our mission to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
Last month, Glaukos began a deal for Celanese to supply its VitalDose drug delivery platform as a component in Glaukos’ iDose TR micro-invasive intraocular implant.